Communiqués Corvus Pharmaceuticals, Inc.

Actions

CRVS

US2210151005

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
2,1 ^USD	+3,45 %		-4,98 %	+19,32 %

07/05	Un initié de Corvus Pharmaceuticals a acheté des actions pour une valeur de 1 000 000 $, selon un récent dépôt auprès de la SEC	MT
07/05	CORVUS PHARMACEUTICALS, INC. : Oppenheimer toujours positif	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference	30/05	AQ
Corvus: Q1 Earnings Snapshot	06/05	AQ
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	06/05	AQ
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024	02/05	AQ
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering	02/05	AQ
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04	AQ
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03	AQ
Corvus: Q4 Earnings Snapshot	19/03	AQ
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	19/03	AQ
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	13/03	AQ
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02	AQ
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	08/02	AQ
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	06/02	AQ
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	23/01	AQ
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T cell Lymphoma Trial	11/12	AQ
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	09/12	AQ
Corvus: Q3 Earnings Snapshot	07/11	AQ
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results	07/11	AQ
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition	02/11	AQ
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	02/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Corvus Pharmaceuticals, Inc.

Actions

CRVS

US2210151005

Communiqués

Filtres